Mill Creek Capital Advisors LLC Has $238,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Mill Creek Capital Advisors LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,581 shares of the biopharmaceutical company’s stock after selling 187 shares during the period. Mill Creek Capital Advisors LLC’s holdings in Gilead Sciences were worth $238,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in GILD. nVerses Capital LLC bought a new position in Gilead Sciences in the third quarter valued at approximately $25,000. HHM Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares during the last quarter. Valued Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares in the last quarter. YANKCOM Partnership acquired a new position in Gilead Sciences during the fourth quarter worth $28,000. Finally, Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter worth $29,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on GILD shares. The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Mizuho lifted their price target on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $84.00 target price on shares of Gilead Sciences in a report on Monday, February 3rd. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $98.39.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $96.14 on Wednesday. The stock has a market capitalization of $119.82 billion, a PE ratio of 1,068.22, a P/E/G ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $100.51. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The business has a fifty day moving average price of $93.07 and a two-hundred day moving average price of $86.99.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. As a group, equities analysts predict that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 572,824 shares of company stock worth $53,611,715. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.